AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Byline: Marie Beerens
Bentley Pharmaceuticals cleared a 12-week base in early November. The stock had corrected 65% from a high of 18.80 in September 2003 to 6.50 in April 2005. It has since more than doubled on strong accumulation. In the past, it had trouble rallying past 14.
Bentley's technologies facilitate the absorption of drugs across various membranes. Its three Spanish subsidiaries sell about 100 generic and branded products to treat cardiovascular, gastrointestinal, neurological and infectious diseases. It keeps growing its European product line through new license agreements with major medical firms.
Earnings grew 150%, 71% and 83% in the …